Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReabold Resources Regulatory News (RBD)

Share Price Information for Reabold Resources (RBD)

Share Price is delayed by 15 minutes
Get Live Data
82.50    1.50 (1.85%)
Bid:
81.00
Ask:
84.00
Spread: 3.00 (3.704%)
Market Cap: £11.96m
RBD Live PriceLast checked at - London Stock Exchange

Intraday Reabold Resources Share Chart

Contract Gain

14 Feb 2006 07:01

Adventis Group PLC14 February 2006 For release 07.00am 14 February 2006 Adventis Group plc Contract Gain Adventis, the specialist multimedia marketing and advertising agency, announcesthat Affiniti (UK) Ltd, its Bucks-based healthcare agency has been awarded theZanidip account following a three-way pitch. The contract, for an undisclosedamount, is now live. Zanidip (lercanidipine), a highly effective calcium blocker used by GP's tolower blood pressure in the treatment of hyper tension, was originally licensedout but the Italian multi-national pharmaceutical group Recordati S.p.A. has nowopened a UK marketing office and will henceforward market the drug itself. Highblood pressure is a problem most common in the elderly, related to poor controlof the working of the heart, and for kidney and liver diseases. Although Affiniti has been involved before in marketing the Zanidip brand,Recordati were looking for a completely fresh approach to move the productforward. Martin Symons, Recordati's UK General Manager, commented: "It was by no means aforegone conclusion for Affiniti - they had to perform on an even playing fieldagainst good competitors, but they came through very strongly. We look forwardto working with them to develop a strong campaign that will move Zanidip to itsrightful position in the marketplace." Affiniti has also won three other pitches against major league competition: - A major product launch for MabThera in severe rheumatoid arthritis for Roche - A major new European campaign in glaucoma for Allergan's Lumigan - A new campaign for Periostat, a dental root treatment for Alliance Said Affiniti's Managing Director, Stuart Tennant: "Across all these recentpitches we have been up against some of the UK's leading healthcare agencieswith big creative reputations - so we know we can compete at the top level. Weare continuing to build our team, our clients' brands - and a strong reputationof our own." - ENDS - Editor's Notes Adventis Group plc is an AIM listed, full service marketing and advertisingagency, providing services to the property, healthcare and financial servicesindustries. Through its six operating companies the company provides a complete range ofcommunication services, including corporate identity programmes, advertisingcampaigns, media planning & buying, literature, public relation, packaging,exhibitions, research and planning, interiors, signage and digital media. Adventis employs over 80 staff in London and the South East. www.adventis.co.uk Recordati is a European pharmaceutical group mainly dedicated to the research,development, manufacturing and marketing of pharmaceuticals. Headquartered inMilan, it has operations in France, Germany, Greece, Ireland, Italy, Spain,Switzerland, the United Kingdom and the United States. Recordati has been listedon the Italian Stock Exchange since 1984. www.recordati.com Enquiries: Affiniti (UK) LtdStuart Tennant, Managing Director 01494 775 213 Adventis Group plc Charles Phillpot, Chief Executive Officer 020 7034 4750 Seymour PierceJohn Depasquale 020 7107 8000 Binns & Co PR Ltd 020 7786 9600Peter Binns / 07768 392 582Annie Evangeli 07778 507 162 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
30th Sep 20087:00 amRNSInterim Results
14th Aug 20085:09 pmRNSHolding(s) in Company
30th Jul 20087:00 amRNSTrading Statement
16th Jul 20084:56 pmRNSTransaction in Own Shares
15th Jul 20082:47 pmRNSTransaction in Own Shares
15th Jul 20088:48 amRNSTransaction in Own Shares
11th Jul 20084:36 pmRNSTransaction in Own Shares
10th Jul 20083:30 pmRNSTransaction in Own Shares
9th Jul 20081:56 pmRNSTransaction in Own Shares
8th Jul 20085:25 pmRNSTransaction in Own Shares
8th Jul 20087:00 amRNSSettlement of Consideration f
7th Jul 20087:00 amRNSTransaction in Own Shares
4th Jul 200810:31 amRNSPayment of Deferred considera
4th Jul 20087:00 amRNSNon Regulatory Announcement
19th Jun 20087:00 amRNSCardif Pinnacle appoints Adve
13th Jun 20084:25 pmRNSFurther re Acquisition
12th Jun 20087:00 amRNSGrant of Share Options
10th Jun 20087:00 amRNSAcquisition
29th May 200812:54 pmRNSResult of AGM and EGM
29th May 20087:00 amRNSAGM Statement
15th May 200811:10 amRNSGrant of Share Options
6th May 20084:51 pmRNSAnnual Report and Accounts
25th Apr 20087:01 amRNSNew Businees Win
10th Apr 20081:43 pmRNSFinal Dividend
10th Apr 20087:01 amRNSFinal Results
4th Apr 20087:01 amRNSNew Contract Win
14th Feb 200811:48 amRNSExercise of ShareOptions &TVR
14th Feb 20087:01 amRNSLaunch of Adventis Integrated
24th Jan 20087:00 amRNSTrading Statement
18th Jan 20085:23 pmRNSDeferred Consideration
17th Jan 200811:53 amRNSDirectors' Interest
20th Dec 200710:04 amRNSOptions, Total Voting Rights
5th Dec 20077:01 amRNSFormation of new division
29th Nov 20073:00 pmRNSOptions and Voting Rights
19th Nov 20077:13 amRNSLeague Table Rankings
18th Oct 20077:02 amRNSRe: Contract Wins
3rd Oct 200712:32 pmRNSAdditional Listing
24th Sep 20077:01 amRNSInterim Results
31st Aug 20075:37 pmRNSTotal Voting Rights
22nd Aug 20077:01 amRNSAccount gains at Adgendamedia
20th Aug 20072:58 pmRNSHolding(s) in Company
17th Aug 200712:34 pmRNSAIM Rule 26 Compliant Website
15th Aug 20077:01 amRNSNew Account Wins
13th Aug 20076:11 pmRNSAdditional Listing
31st Jul 200712:52 pmRNSTotal Voting Rights
23rd Jul 20077:00 amRNSTrading Update
29th Jun 20074:33 pmRNSTotal Voting Rights
22nd Jun 20077:02 amRNSRe: Contract Wins
11th Jun 20079:28 amRNSGrant of Share Options
6th Jun 20073:29 pmRNSre Earn Out

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.